Cargando…

A Randomized Clinical Trial of Intratracheal Administration of Surfactant and Budesonide Combination in Comparison to Surfactant for Prevention of Bronchopulmonary Dysplasia

OBJECTIVES: Bronchopulmonary dysplasia (BPD) remains a major problem in preterm infants occurring in up to 50% of infants born at < 28 weeks gestational age. Inflammation plays an important role in the pathogenesis of BPD. This study was conducted to evaluate the efficacy of intratracheal budeson...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gharehbaghi, Manizheh M., Ganji, Shalale, Mahallei, Majid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OMJ 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376750/ https://www.ncbi.nlm.nih.gov/pubmed/34447583 http://dx.doi.org/10.5001/omj.2021.84

Ejemplares similares

The efficacy of intratracheal administration of surfactant and budesonide combination in the prevention of bronchopulmonary dysplasia
por: Gharehbaghi, Manizheh Mostafa, et al.
Publicado: (2021)

Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial
por: Manley, Brett J., et al.
Publicado: (2023)

Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial
por: Francis, Kate L, et al.
Publicado: (2023)

Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns – A systematic review
por: Moraes, Lucas Hirano Arruda, et al.
Publicado: (2022)

Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE)
por: McEvoy, Cindy T., et al.
Publicado: (2020)

Endotracheal Surfactant Combined With Budesonide for Neonatal ARDS
por: Deliloglu, Burak, et al.
Publicado: (2020)

Genetic Variants of Surfactant Proteins A, B, C, and D in Bronchopulmonary Dysplasia
por: Pavlovic, J., et al.
Publicado: (2006)

Intra‐tracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants
por: Moschino, Laura, et al.
Publicado: (2021)

Pulmonary surfactant combined with budesonide in the treatment of neonatal respiratory distress syndrome
por: Guo, Hongxing, et al.
Publicado: (2023)

Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem
por: Arroyo, Raquel, et al.
Publicado: (2021)

Early administration of surfactant via a thin intratracheal catheter in preterm infants with respiratory distress syndrome: Feasibility and outcome
por: Mohammadizadeh, Majid, et al.
Publicado: (2015)

Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration
por: Chen, Chung-Ming, et al.
Publicado: (2019)

Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China
por: Xu, Chun-cai, et al.
Publicado: (2022)

Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo
por: Baer, Brandon, et al.
Publicado: (2020)

Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging
por: Zecchi, Riccardo, et al.
Publicado: (2021)

Comparison of mortality and short-term outcomes between classic, intubation-surfactant-extubation, and less invasive surfactant administration methods of surfactant replacement therapy
por: Kim, Seung Yeon, et al.
Publicado: (2023)

Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
por: Um, Soo Jung, et al.
Publicado: (2013)

Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant
por: Ballard, Philip L., et al.
Publicado: (2021)

Novel Approaches to Surfactant Administration
por: Gupta, Samir, et al.
Publicado: (2012)

Intratracheal Keratinocyte Growth Factor Enhances Surfactant Protein B Expression in Mechanically Ventilated Preterm Pigs
por: Krishnan, Ramesh, et al.
Publicado: (2021)

Evaluation of intratracheal salbutamol effects in addition to surfactant in the clinical course of premature neonates with respiratory distress syndrome
por: Goudarzi, Razieh Moazami, et al.
Publicado: (2023)

Effectiveness of intratracheal salbutamol in addition to surfactant on the clinical course of newborns with respiratory distress syndrome: a clinical trial
por: Dehdashtian, Masoud, et al.
Publicado: (2016)

Consecutive daily administration of intratracheal surfactant and human umbilical cord-derived mesenchymal stem cells attenuates hyperoxia-induced lung injury in neonatal rats
por: Chou, Hsiu-Chu, et al.
Publicado: (2021)

Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study
por: Keller, Roberta L., et al.
Publicado: (2012)

Dose of budesonide with surfactant affects lung and systemic inflammation after normal and injurious ventilation in preterm lambs
por: Hillman, Noah H, et al.
Publicado: (2020)

Implementation of Surfactant Administration through Laryngeal or Supraglottic Airways (SALSA): A Jordanian NICU’s Journey to Improve Surfactant Administration
por: Abu Leyah, Naser Aldain A., et al.
Publicado: (2022)

An Update on the Prevention and Management of Bronchopulmonary Dysplasia
por: Hennelly, Marissa, et al.
Publicado: (2021)

Comparison of minimally invasive surfactant therapy with intubation surfactant administration and extubation for treating preterm infants with respiratory distress syndrome: a randomized clinical trial
por: Sabzehei, Mohammad Kazem, et al.
Publicado: (2021)

Prophylactic Administration of Surfactant in Extremely Premature Infants
por: Koch, Lutz, et al.
Publicado: (2010)

Evaluation of methods of surfactant administration in the delivery suite?
por: Ambulkar, Hemant, et al.
Publicado: (2021)

Surfactant
por: Soll, Roger F., et al.
Publicado: (2013)

Budesonide with surfactant decreases systemic responses in mechanically ventilated preterm lambs exposed to fetal intra-amniotic lipopolysaccharide
por: Hillman, Noah H., et al.
Publicado: (2020)

Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts
por: Anderson, Connie D., et al.
Publicado: (2021)

Drug therapy for the prevention and treatment of bronchopulmonary dysplasia
por: Iyengar, Anjali, et al.
Publicado: (2015)

NOVEL BIOMARKERS OF BRONCHOPULMONARY DYSPLASIA AND BRONCHOPULMONARY DYSPLASIA-ASSOCIATED PULMONARY HYPERTENSION
por: Sahni, Mitali, et al.
Publicado: (2020)

Surfactant administration in neonates: A review of delivery methods
por: Nouraeyan, Nina, et al.
Publicado: (2014)

Less invasive surfactant administration and complications of preterm birth
por: Härtel, Christoph, et al.
Publicado: (2018)

Less invasive surfactant administration (LISA): chances and limitations
por: Herting, Egbert, et al.
Publicado: (2019)

An Apparatus for the Intratracheal Administration of Ether
por: Shipway, F. E.
Publicado: (1913)

Phenotypes of Bronchopulmonary Dysplasia
por: Wang, Shih-Hsin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vortu21ugifmva8pac85e3tf41